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Abstract
Objective: Disturbances in wound healing in patients
with hyperglycaemic blood sugar values are a common
clinical problem. Recent studies identified PPARα-lig-
ands as potential skin therapeutic agents. The aim of
this study was to investigate the effects of oral fenofi-
brate treatment on dermal wound healing and micro-
circulatory parameters in diabetic mice.
Methods: Dermal wounds were created in CD-1 mice.
Mice were randomized into four treatment groups: di-
abetic mice treated (dbf) or not-treated with fenofi-
brate (dbnf). As controls served non-diabetic mice
treated (ndf) or not-treated with fenofibrate (ndnf). At
various points in time microcirculation was analyzed
by intravital fluorescent microscopy to determine
wound surface area, vessel diameter, plasma leakage,
functionalcapillary density, and leukocyte/endothelium
interaction.
Results: The dbf-mice showed a significantly increased
diameter of the venules and the arterioles up to 3 days
after wound creation compared to dbnf-mice. Howev-
er, wound healing was not improved in dbf-compared
to dbnf-mice. Surprisingly, all microcirculatory para-
meter (vessel diameter, plasma leakage and functional
capillary density) were not deteriorated in dbnf- com-
pared to ndnf-mice.
Conclusion: We confirm that high blood sugar values
lead to a delayed wound healing, but this could not
traced back to altered microcirculatory patterns. Fur-
thermore, in dbf-mice an improved vasodilatatory
function of small vessels could be detected, but with
no substantial effect on wound healing. Further stud-
ies are needed to clarify, if topical application of
fenofibrate might be beneficial.
Key words: wound healing, fenofibrate, microcircula-
tion, diabetes, peroxisome proliferator activated recep-
tor (PPAR)
INTRODUCTION
Diabetic ulcers complications are a leading cause of
hospitalization and amputation. Ten to 15% of the 20
million individuals with diabetes are at risk of devel-
oping diabetic ulcers (Centers of Disease Control and
Prevention 1998). Standard therapy involves the use of
dressings to protect the wound bed from trauma and
to absorb exsudate, offloading of high pressure on the
wound bed e.g. by prescribing protective footwear, and
wound bed preparation to accelerate endogenous heal-
ing. However these measures are often deficient to
heal all diabetic ulcers when the patient's own intrinsic
wound healing system is insufficient (Falanga et al.
2005). Therefore, the search for new targets and their
synthetic ligands which improve wound healing are
highly recommended.
In recent years several studies support a link be-
tween the 3 peroxisome proliferator activated recep-
tors (PPAR α, δ, and γ) and diabetes, obesity, dyslipi-
demia, and inflammation. Increased recognition of a
role for PPARs in metabolic- and inflammation regula-
tion came following the discovery of fibrates and thia-
zolidinediones were synthetic ligands for PPARα and
PPARγ (Issemann et al. 1990, Formann et al. 1997,
Lehmann et al. 1995). PPARα influences intracellular
lipid and carbohydrate metabolism through direct
transcriptional control of genes involved in peroxiso-
mal and mitochondrial β-oxidation pathways, uptake
of fatty acids, and triglyceride catabolism. Further-
more, PPARα agonists inhibit the expression of sever-
al inducible factors which are implicated in endothe-
lial, macrophage and smooth muscle cell function
(Lefebvre et al. 2006). Moreover, PPARα activation re-
sults in an anti-inflammatory action as demonstrated
in the PPARα-deficient mouse model (Devchand et al.
1996). Clinically, these molecular actions of PPARα
activators culminate in a reduction of circulating in-
flammatory markers and a reduction of the progres-
sion of atherosclerotic lesions (Lefebvre et al. 2006).
The ability of PPARα to improve metabolic alter-
ations suggests that PPARα may be beneficial in the
prevention or treatment of patients with diabetes mel-
litus and their associated complications. Therefore, we
tested the effect of the PPARα agonist fenofibrate on
wound healing and circulatory parameters in healthy
and diabetic mice.
MATERIALS AND METHODS
Animals: Male CD1 mice (26-38 g body weight) were
obtained from Charles River, Sulzfeld, Germany. The
animals had access to standard laboratory feed (18000
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sniff, Spezialdiaeten, Soest, Germany) and tap water
ad libitum. The mice were housed individually at 21 ﾰC
temperature in a 12 hour dark/12 hour light cycle. The
principles of laboratory animal care were followed
(Ruhr-University Bochum, No.105/6). For the experi-
ments, mice were anesthetized by spontaneous inhala-
tion of isoflurane-N2O (FiO2 0.35, 0.015 L/L Isoflu-
rane, Forene, Abbott GmbH, Wiesbaden, Germany)
and placed on a heated custom made observation plat-
form to maintain body temperature at 37.0 ﾰC.
Induction of diabetes: Under general anaesthesia mice
were assigned up to three intraperitoneal injections on
day -14, -11 and -7 of 60 mg/kg streptozotocin (N-
Methylnitrosocarbamoyl-D-glucosamine; Sigma, Dei-
senhofen, Germany) per kg body weight to induce dia-
betes. The induction of diabetes was carried out 2
weeks prior to the start of the experiments. Blood glu-
cose level was determined by means of analysis of tail
vein blood every day after the first application
(akkucheck). Animals with blood glucose levels over
350 mg/dl were accepted for the study.
Hair depilation on mouse ear: In order to get good and
analysable microcirculatory records we depilated
mouse hair on the ears with pilca depilation cr￨me on
day –1, +6, + 13 and +20. The wound area was pro-
tected with tegaderm foil during depilation so that it
did not get in contact with the cr￨me.
Wound creation: Wounds were created as described
previously (Langer et al. 2002, Langer et al. 2004).
Briefly, the area selected for wounding on the dorsal
side of the ear was marked with an O-shaped ink
stamp of a diameter of 2.5 mm. Using this mark, a
full-thickness dermal layer down to the underlying car-
tilage was excised by means of microsurgical scissors
(Medicon, Tuttlingen, Germany) under a surgical mi-
croscope. This preparation provided a full-thickness
dermal wound of approx. 5 mm2 with a depth of ap-
prox. 120 ﾵm.
Application of fenofibrate: Primarily, we examined the
minimal and maximal eating dose of a representative
group of ten diabetic and non-diabetic mice. The min-
imal eating dose was 3g. In order to get sure that a
mice with a minimal weight of 25 g gets its total daily
dose, fenofibrate (10mg/kgKG/d) was mixed into
normal laboratory mice food (18000 IE/kg Vit. A,
1280 IE/kg Vit. D3, 120 mg/kg Vit. E; sniff, Spezial-
diaeten, Soest, Germany) in a concentration of 0.0833
mg per gram food.
Experimental groups: Mice were randomized into four
treatment groups: diabetic mice treated (dbf, N = 10)
or not-treated with fenofibrate (dbnf, N = 9). As con-
trols served non-diabetic mice treated (ndf, N = 12) or
not-treated with fenofibrate (ndnf, N = 10).
Measurement using intravital fluorescent microscopy:
Following exteriorization of the ear by means of three
permanent suture loops the animal was placed on a
computer controlled stage to perform the investiga-
tions with an intravital fluorescent microscope (Harris
et al. 1997). A 4-fold and a 20-fold water immersion
objective (Zeiss Axiotech, Zeiss, Oberkochen, Ger-
many) was used, resulting in total magnifications of
57-fold (wound surface measurements). The X-Y co-
ordinates of the region of interests (ROI) were
recorded (AxioVision 3.0, Zeiss, Germany) and their
position stored on the computer to ensure relocation
of identical areas throughout the study. In addition,
drawings of the microcirculatory areas were made to
ensure relocation of the ROI. For contrast enhance-
ment of the plasma 0.1 ml of 2% fluorescein isothio-
cyanate (FITC) labeled Dextran (MW 150,000; Sigma
Chemicals Co., St. Louis, USA) was injected prior to
the measurements. For visualization of leukocytes, the
fluorescent marker Rhodamine 6G (Sigma, Chemicals
Co., St. Louis, USA) was given i.v. as a bolus of 0.15
mg/kg 10 minutes before the measurements. The im-
ages were recorded using a charge-coupled device
video camera (AVT-BC 71, AVT- Horn, Aalen, Ger-
many) on super VHS video tapes (Sony, Cologne, Ger-
many). At the end of the observations the animals
were released to their cages. Microscopic observations
were performed prior to wounding (day 0) and repeat-
ed on day 3, 7, 14 and 21 after wound creation. At the
end of the experiments the animals were killed under
general anaesthesia by an overdose of i. p. given pen-
tobarbital.
Measurement of wound surface area: While restrained
in the observation platform images of the wound sur-
face area under the intravital microscopy setup were
performed with a total magnification of 57-fold. At
this magnification the wound occupied a single micro-
scopic field and allowed for its observation on the
monitor. From these digital images the wound surface
area was calculated by a digital planimetric mode inte-
grated into the computer assisted image analysis sys-
tem CapImage (Dr. Zeintl, Heidelberg, Germany) and
expressed as mm2 (Klyscz et al. 1997).
Microcirculatory parameters: Microcirculatory mea-
surements were made at 3 ROIs located at the edge of
the wound. Inside those ROIs a total of 3 venules, 3
arterioles as well as 3 capillary fields per animal were
recorded. The recording time for each field of obser-
vation was 20 seconds. The following parameters were
analyzed: 1. Diameter of arterioles and venules [ﾵm],
2. Functional capillary density (FCD) [cm/cm2], 3.
Macromolecular leakage of the plasma marker FITC-
Dextran from venules [Ie/Ii], 4. The number of ad-
herent leukocytes in venules [n/100 ﾵm]. FCD is de-
fined as the length of red blood cell perfused capillar-
ies per observational area. This parameter is used as an
index for tissue perfusion (Nolte et al. 1995). Macro-
molecular leakage of the plasma marker FITC-Dex-
tran out of vessels is a measure of endothelial integri-
ty (Harris et al. 1996). It is given as the ratio of the
fluorescence intensities measured outside vs. inside a
vessel. According to their interaction with the en-
dothelium, leukocytes were defined as adherent in the
case they did not move from microvascular endotheli-
um during the observation time of 20 seconds (Nolte
et al. 1994, Terajima et al. 2000).
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gram SigmaStat (Jandel Scientific, Erkrath, Germany)
was used for statistical analysis of the data. Data is
given as mean ﾱ standard deviation (sd). Comparison
between groups was performed using a non-paramet-
ric Kruskal-Wallis test followed by Dunn’s method. A
p < 0.05 was considered statistically significant.
RESULTS
Blood glucose values and body weight: Neither the non-
diabetic- (ndnf vs. ndf) nor the diabetic (dbnf vs. ndf)
groups showed a difference concerning their blood
glucose values. These results suggest that fenofibrate
hasn`t an impact on blood glucose control (Fig. 1).
Wound surface area: The diabetic-mice showed irre-
spective of their treatment alignment a significantly
worsened wound healing compared to their non-
diabetic controls (Fig. 2). At day 21 only two-thirds of
the wound area were closed in the diabetic
mice whereas in the non-diabetic mice the wound
was almost completely closed. These results suggest
that wound healing problems exist at early stages
of diabetes development, keeping in mind that
diabetes was induced by streptozotocin only two
weeks prior the examination. Furthermore, the
wound surface area was compared among the non-
diabetic mice (ndf-mice vs. ndnf-mice), with a tenden-
cy for a faster wound healing in the ndf-mice, but
a significant difference could not be detected at
any time point. The same holds true for the dbf-
mice when compared to the dbnf-mice. These
observations suggest that fenofibrate treatment leads
in our model not to an improvement of macroscopic
wound healing neither in non-diabetic nor in diabetic
mice.
Microcirculatory parameters (Table 1): The arteriolar
diameter increased significantly from day 0 to 3 in the
dbf-mice, and decreased thereafter to the starting val-
ue. In contrast, the arteriolar diameter of the other
groups (ndnf, ndf, dbnf) remained nearly unchanged.
Furthermore, the dbf-mice showed a significant va-
sodilatation of the venules between day 0 and day 3,
whereas in the other groups such an effect could not
be observed. In addition, in all groups the FCD in-
creased significantly until day 7, but with no difference
among the groups. Furthermore, a significant accumu-
lation of leukocytes could be observed in all experi-
mental groups. The rolling leukocytes occurred in a
larger number on day 3 and the sticky leukocytes could
be detected in a larger amount on day 3 and 7. Con-
cerning the endothelial leakage a significant venous ex-
travasation could be observed in all groups on day 3.
In both diabetic groups there was a tendency to more
diffusion of the macromolecular plasma marker
FITC-Dextran, but this remained not statistical signifi-
cant (data not shown).
DISCUSSION
This study demonstrates an improvement of endothe-
lial dysfunction in diabetic mice treated with fenofi-
brate (dbf-mice). However, an effect on wound healing
and blood glucose control could not be demonstrated.
It has been shown that hyperglycaemic blood glu-
cose levels lead to an altered lipid profile including an
elevation of triglycerides and free fatty acids (FFA),
which in turn are toxic to endothelial cells leading to
vascular dysfunction (Steinmetz 2003, Mittermayer et
al. 2007). Fibrates are a widely used class of lipid-regu-
lating agents, exerting a variety of effects on lipid- and
lipoprotein metabolism, particularly reduction of
triglycerides and FFA (Staels et al. 1998). In our study
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Fig. 1. Blood glucose values were significantly higher in dbf-
(white triangle) and dbnf-mice (black triangle) compared to
ndf- (black circle) and ndnf-mice (white circle) over the
whole study period, but a substantial effect of fenofibrate
treatment on blood glucose control could not be observed.
Values are represented mean ﾱ sd.
Fig. 2. Wound surface area was significantly higher in dbf-
(white triangle) and dbnf-mice (black triangle) compared to
ndf- (black circle) and ndnf-mice (white circle) at day 14 and
21, but a significant effect of fenofibrate treatment on macro-
scopic wound healing could not be observed. Values are rep-
resented mean + sd. * p < 0.05
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ameter of the venules as well as of the arterioles up to
3 days after wound creation compared to dbnf-mice.
This effect seems not be a direct interaction of fenofi-
brate with PPARα-receptors in the vessel wall, be-
cause in ndf-mice such an effect could not be ob-
served. The mechanisms by which fenofibrate leads to
an improved vasodilatation remains to be speculative,
but there are good clinical data that fibrates improve
endothelial dysfunction in patients with type 2 dia-
betes by modifying hyperglycaemia-induced athero-
genic lipid profile (reduction of FFA and triglycerides,
increased HDL-C) and reduction of oxidative stress
(Evans et al. 2000).
Wound repair requires the integration of interde-
pendent processes and signals that involve, among
others, soluble mediators, inflammatory cytokines pro-
duced by a variety of cell types, cell proliferation and
migration, cell differentiation and production of extra-
cellular matrix components. The hypothesis that
PPARα participates in the control of the inflammato-
ry process during wound repair is reinforced by the
observation that PPARα-/- mice show an impaired
wound healing due to uncontrolled inflammation at
wound site (Michalik et al. 2001). Furthermore, it has
been shown that topical application of a PPARα-ago-
nist to mice with hyperproliferative skin disorders nor-
malizes cell proliferation and promotes epidermal dif-
ferentiation and correct the cutaneous pathology
(K￶m￼ves et al. 2000). Therefore, PPARα-activators
have been identified as potential skin therapeutic
agents. However, in our study systemic application of
fenofibrate by oral gavage in a therapeutical dose im-
proved neither in the diabetic nor in the non-diabetic
mice the wound healing process significantly. There-
fore, further studies are necessary to clarify if topical
application of fenofibrate or other PPARα-activators
may improve wound healing in diabetic animals.
The wound healing process was significantly im-
paired in the diabetic mice compared to the non-dia-
betic control mice, despite diabetes was induced only 2
weeks prior starting the experiments. These results are
in agreement with those obtained by others (Langer et
al. 2002). Surprisingly, the impaired wound healing
could not traced back to an altered microcirculation,
because all the examined parameter (vessel diameter,
red blood cell velocity, plasma leakage and functional
capillary density) were not deteriorated in the dbnf-
mice compared to the ndnf-mice. These results sug-
gest that the impaired wound healing process in mice
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Table 1. Microcirculatory parameters of the 4 different treatment groups at predefined points in time.
Parameter day ndf ndnf dbf dbnf
FCD (in cm/cm2) 0 187.2 ﾱ 18.2 199.0 ﾱ 11.4 190.8 ﾱ 14.1 199.5 ﾱ 8.7
3 215.5 ﾱ 16.6 210.8 ﾱ 15.8 201.9 ﾱ 12.7 211.0 ﾱ 10.3
7 229.5 ﾱ 14.5X 222.1 ﾱ 13.9X 212.0 ﾱ 10.9X 215.8 ﾱ 6.8X
14 214.5 ﾱ 19.5 209.4 ﾱ 8.9 205.4 ﾱ 10.6 208.1 ﾱ 9.4
21 195.1 ﾱ 14.6 202.4 ﾱ 11.6 195.1 ﾱ 12.0 198.3ﾱ 9.6
Diameter of arterioles (mm) 0 41.0 ﾱ 12.3 43.5 ﾱ 8.3 37.7 ﾱ 2.9 42.0 ﾱ 6.6
3 41.0 ﾱ 9.2 45.6 ﾱ 10.5 45.5ﾱ 3.8 X 44.2 ﾱ 7.8
7 40.9 ﾱ 8.1 46.6 ﾱ 10.3 41.6 ﾱ 2.5 45.5 ﾱ 5.0
14 39.6 ﾱ 10.4 45.1 ﾱ 10.0 40.2 ﾱ 2.9 42.7 ﾱ 5.4
21 42.8 ﾱ 12.8 43.4 ﾱ 9.6 40.1 ﾱ 2.4 42.0 ﾱ 6.3
Diameter of venules (mm) 0 82.8 ﾱ 18.3 82.8 ﾱ 12.1 83.9 ﾱ 7.8 78.5 ﾱ 10.3
3 85.5 ﾱ 22.3 85.8 ﾱ 15.4 94.7 ﾱ 8.1* 81.1 ﾱ 13.9
7 82.4 ﾱ 19.6 83.6 ﾱ 16.3 90.3 ﾱ 8.4 76.7 ﾱ 13.0
14 83.3 ﾱ 17.1 83.9 ﾱ 13.3 86.1 ﾱ 8.2 75.6 ﾱ 11.2
21 80.8 ﾱ 20.2 81.7 ﾱ 12.2 85.0 ﾱ 7.8 77.1 ﾱ 9.7
Rolling leukocytes 0 11.2 ﾱ 2.1 12.0 ﾱ 3.1 12.5 ﾱ 2.0 13.0 ﾱ 1.5
(n/100mm/20sec) 3 14.2 ﾱ 1.9X 15.5 ﾱ 2.5X 15.4 ﾱ 1.4X 16.0 ﾱ 1.1X
7 11.8 ﾱ 1.7 13.1 ﾱ 1.9 12.7 ﾱ 1.2 13.2 ﾱ 1.5
14 11.5 ﾱ 1.8 11.6 ﾱ 2.7 11.9 ﾱ 0.9 12.1 ﾱ 1.3
21 11.0 ﾱ 1.5 11.6 ﾱ 2.4 12.1 ﾱ 0.9 12.0 ﾱ 0.9
Sticky leukocytes 0 3.1 ﾱ 0.8 3.6 ﾱ 1.2 4.0 ﾱ 1.2 3.8 ﾱ 0.7
(n/100mm/20sec) 3 4.9 ﾱ 1.4X 5.9 ﾱ 0.9X 5.4 ﾱ 1.1X 5.3 ﾱ 1.0X
7 4.8 ﾱ 0.8X 6.1 ﾱ 1.2X 4.6 ﾱ 0.8X 5.2 ﾱ 1.1X
14 3.9 ﾱ 0.7 5.1 ﾱ 1.9 3.9 ﾱ 0.7 4.6 ﾱ 0.5
21 3.5 ﾱ 1.0 4.0 ﾱ 1.7 3.6 ﾱ 1.0 3.8 ﾱ 0.8
X < 0.05 vs. baseline, * p = 0.007 vs. baseline. Mean ﾱ sd.
4. Schneider:Umbruchvorlage  03.02.2009  12:48 Uhr  Seite 68with short diabetes duration is primarily a problem of
the local wound environment. Recently, it has been
shown that some of the resident cells in diabetic ul-
cers are phenotypically altered. Fibroblasts isolated
from diabetic foot ulcers are probably senescent and
show a decreased proliferative response to growth fac-
tors (Loot et al. 2002). Similar studies in other types of
wounds are in agreement with these findings, having
shown decreased fibroblast response to TGFβ1,
platelet-derived growth factor, and other cytokines
(Hasan et al. 1997, Agren et al. 1999, Stanley et al.
2005). Evidence suggests that phenotypic changes in
wound cells are not due only to replicative senescence,
but are perhaps caused by more complex interactions
between the resident cells and the wound (Stephens et
al. 2003). Wound fibroblasts do show decreased ex-
pression of type 2 TGFβ receptors, with impaired
phosphorylation of transduction signals, including
Smad2, Smad3, and mitogen-activated protein kinase
(Kim et al. 2003). Although much more work is need-
ed to clearly define the phenotypical abnormalities in
diabetic wound cells, these findings have clear-cut im-
plications for therapeutic intervention. For example,
growth factors delivered in a simplistic topical ap-
proach might not find a regularly suitable and respon-
sive target cell population.
Other cellular abnormalities exist in diabetes. Exces-
sive activation of some MMPs, such as MMP9, can im-
pair cell migration and lead to breakdown of some nec-
essary matrix proteins and growth factors (Signorelli et
al. 2005). Although there is no direct evidence that the
proliferative activity of keratinocytes is affected in dia-
betes, migration may well be impaired and studies with
cells from diabetic wounds are needed (Acikgoz et al.
2004). Therefore, beside correction of hyperglycemia,
proper debridement of diabetic ulcers corrects many
more subtle abnormalities, at least partly, by removal of
altered resident cells and matrix material.
In summary, we confirm that that high blood sugar
values lead in a very short time frame to an impaired
wound healing process, but this alteration could not
traced back to altered microcirculatory patterns. Fur-
thermore, in diabetic mice systemic fenofibrate treat-
ment leads to an improved vasodilatatory function of
small vessels in the early phase of wound healing (first
3 days). However, this corrects not the delayed wound
healing in diabetic mice. Further studies are needed to
clarify, if topical application of fenofibrate might im-
prove wound healing.
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